AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: XTANDI (Astellas Pharma Inc.) (xtandi.com)
This is a high-integrity medical website that prioritizes regulatory transparency over marketing hyperbole. The BS score of 11 reflects a site that provides substantial evidence for every claim, with only minor points lost to necessary repetition and standard patient-engagement terminology. It is an authoritative resource for both patients and healthcare providers.
Incorporate National Clinical Trial (NCT) identifiers into each clinical results section to allow for one-click verification of raw data on government registries. Replace marketing-heavy headings like ‘Real XTANDI Xperiences’ with ‘Patient Case Study Videos’ to better align with the clinical tone of the rest of the site. Include specific peer-reviewed journal citations (e.g., NEJM or Lancet) next to the 5-year survival statistics. Add a technical glossary explaining the statistical difference between ‘median’ and ‘average’ to further empower high-literacy patients and reduce perceived ambiguity.
The site exhibits high information density, particularly on the clinical-trials page, which avoids fluff headings in favor of substance-led markers like ‘XTANDI slowed disease progression.’ The body substance ratio is exceptionally high, citing specific patient counts (e.g., ‘154 out of 574 deaths’) and median survival deltas (e.g., ’35 months vs 31 months’). Information Density points were primarily triggered by the repetition of the ‘4 types’ value proposition, which appears in H1s, meta descriptions, and body text across all four analyzed pages. A minor penalty was applied for heading fluff in the patient experience sections, such as ‘The Power of Support.’
AI systems don't validate syntax — they validate identity, relationships, and meaning. Get a Clinical Structured Data Diagnosis to reveal what AI sees versus what it should see.
There is zero semantic drift between the homepage signal and the sub-page substance. The homepage H1 claims approval for 4 types of advanced prostate cancer, and the Clinical Results page provides dedicated, granular data sections for all four (mCSPC, mCRPC, nmCRPC, and nmCSPC). Messaging regarding financial support and the Doctor Discussion Guide is consistently maintained across the site’s hierarchy without contradiction.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
Trust theatre is minimal but present in the ‘Real XTANDI Xperiences’ sections, where review_count values of 3 and 2 are noted in the data without verified external proof_links_count. However, this is significantly offset by the site’s primary proof paths: the full Prescribing Information PDF and the rigorous ‘Select Safety Information’ blocks that provide a balanced view of risks. The site avoids the ‘Claims without evidence’ trap by grounding every efficacy percentage in a specific trial cohort.
The proof density is high, with the site providing specific clinical trial data for every major efficacy claim. The ratio of verifiable evidence to marketing fluff is approximately 8:1, with nearly every H4 and H5 heading on the clinical page serving as a data delivery mechanism rather than a vague assertion.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site uses several industry clichés and template fingerprints, including ‘FDA approved,’ ‘clinical trial data,’ and ‘Patient Resources.’ These matches (6 total) resulted in a minor 3-point penalty for generic industry language. However, the value proposition is clearly differentiated and cannot be simply copy-pasted onto competitors due to the specific regulatory indication for four distinct stages of prostate cancer.
No authority gaps were detected. The manufacturer (Astellas) is clearly identified in the footer and structured data, and the drug is identified by its non-proprietary name (enzalutamide). The site does not rely on unverifiable ‘expert’ endorsements but instead points users toward their own healthcare professionals via the Doctor Discussion Guide.
There is no disconnect between marketing claims and clinical performance. Bold assertions like ‘61% less risk of cancer progression’ are immediately followed by raw trial numbers (89 out of 576 patients) and a clear definition of how progression was measured (scans or death). This level of transparency is characteristic of compliant pharmaceutical communications.
Medical Devices, Pharma & Biotech BS: XTANDI (Astellas Pharma Inc.) (xtandi.com)
The website perfectly aligns with the Pharmaceutical and Biotech industry, specifically within the oncology therapeutic area. The presence of extensive Important Safety Information (ISI), clinical trial data sets, and regulatory approval claims confirms its classification.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The BS score was driven by Pillar 1 (Information Density) due to the high repetition of the core regulatory claim and Pillar 4 (Commodity Fingerprint) due to the use of standard pharmaceutical marketing jargon. Pillar 3 (Trust and Proof) contributed 2 points because the patient stories lack verified external proof links, despite the high quality of the surrounding clinical data.”